Vildagliptin-Metformin: Is it a causative of cardiac muscle failure in Type 2 Diabetic patients?
<p>Vildagliptin is an oral anti-hyperglycaemic agent, commonly called an anti-diabetic medication that belongs to the family of medications known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors. It is a medicine that is used to treat Type 2 Diabetes Mellitus [1]. </p>
Saved in:
Main Author: | YRKM Sai (Author) |
---|---|
Format: | Book |
Published: |
International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications,
2021-09-24.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metformin: Beyond Diabetes
Published: (2020) -
Validity of Ratings of Perceived Exertion in Patients with Type 2 Diabetes
by: Jessica L. Unick, et al.
Published: (2014) -
Management of type 2 Diabetes in patients with Chronic Kidney Disease
by: Beena Bansal, et al.
Published: (2017) -
Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy
by: Michael Ashamalla, et al.
Published: (2018) -
Echocardiography in Heart Failure and Cardiac Electrophysiology
Published: (2016)